Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas

Neoadjuvant Therapy Clinical Trial

Official title:

Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03178032
• Other study ID #: D24-DIPG
• Status: Completed
• Phase: Phase 1
• Start date: May 26, 2017
• Est. completion date: January 31, 2021

Study information

• Verified date: April 2023
• Source: Clinica Universidad de Navarra, Universidad de Navarra
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Oncolytic adenovirus for pediatric naive DIPG, to be infused after tumor biopsy through the same trajectory in the cerebellar peduncle.

Description:

Diffuse pontine gliomas (DIPG) are one of the most lethal pediatric tumors. All treatment approaches for these tumors have failed, leaving a terrible prospect with median survival under one year, and survival at 5 years virtually of zero. Moreover, most of the long term survivors suffer from long-term side effects of the aggressive treatment. Thus, new therapeutic strategies are required that allow not only for more effective treatments of these tumors but also that defer the severe side effects derived from the current therapeutic choices. DNX-2401 is an oncolytic virus engineered to replicate specifically in tumor cells with an abnormal retinoblastoma (RB) pathway. Moreover, this virus infects cells through integrins, which are more abundant in glioma cells. Here we propose a phase I, unicentric, non-randomized clinical trial to study the safety and potential efficacy of intratumoral administration of DNX-2401 in DIPG. The virus administration will be done after stereotactic tumor biopsy, using the same trajectory, after verification of catheter position with intraoperative MRI. After 3-4 weeks patients will receive standard radiotherapy and/or chemotherapy. The primary objective is to confirm the safety of the target dose known from adults trials. Secondary endpoints are overall survival at 12 months (OS12), percentage of responses and induced immune response against tumor. The follow up includes close monitoring of neurological status, blood tests and brain MRI. If this trial shows evidence of safety and efficacy will propel a multicenter clinical trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: January 31, 2021
• Est. primary completion date: January 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

1. Informed consent OF PATIENT OR PARENTS

2. Patient must be, in the investigator opinion, able to comply with all the protocol procedures.

3. Age 1 - 18 years

4. Negative pregnant blood test in case of fertile women (A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

5. Patient newly diagnosed of DIPG in MRI

6. Lansky Performance Status = 70 before inclusion

7. Lesion considered by the investigator to be accessible for stereotactic biopsy. Lesion location will allow injection without entrance of virus in the ventricular system.

8. No previous treatment for DIPG

Exclusion Criteria:

1. Severe infections or intercurrent medical conditions including, but not limited to, severe renal, hepatic, heart or bone marrow failure, that, on investigator´s criteria, do not allow the inclusion. Patients must be afebrile at baseline [i.e., < 38 degrees (Cº)].

2. Investigational medication in the previous 30 days.

3. Subjects with immunodeficiency, autoimmune conditions or active hepatitis.

4. Any medical or psychological condition that might interfere with the subject's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.

5. Tumor with multiple locations or doubt in MRI of a DIPG.

6. Pregnant or breast-feeding females will be excluded, due to the risk for the fetal development of a recombinant virus containing genes related to cellular growth and differentiation.

7. Severe bone marrow hypoplasia.

8. AST (aspartate transaminase) and/or ALT (alanine transaminase)> 3 times over upper normal laboratory level

9. Neutrophils < 1 x 109/L

10. Thrombocytes = 100 x 109/L

11. Hemoglobin < 9g/dl

13. Patients with Li-Fraumeni Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways.

14. Vaccinations of any kind within 30 days prior to DNX-2401 administration. 15. Transfusions or medications (G-CSF) to treat pancytopenia or other hematological conditions within 28 days of baseline.

Related Conditions & MeSH terms

• Brainstem Glioma
• Diffuse Intrinsic Pontine Glioma
• Glioma
• Neoadjuvant Therapy

Intervention

Biological:
• DNX-2401
Brain infusion of the virus through the cerebellar peduncle

Locations

Country	Name	City	State
Spain	Clinica Universidad de Navarra	Pamplona	Navarra

Sponsors (3)

Lead Sponsor	Collaborator
Clinica Universidad de Navarra, Universidad de Navarra	Alcyone Lifesciences, Inc., DNAtrix, Inc.

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15;67(24):11499-504. doi: 10.1158/0008-5472.CAN-07 — View Citation

Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D, van der Hoeven EJ, Gidding CE, de Bont ES, Eshghi OS, Reddingius R, Peeters CM, Schouten-van Meeteren AY, Gooskens RH, Granzen B, Paardekooper GM, Janssens GO, — View Citation

Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety, tolerability and toxicity of DNX-2401 injected in the cerebellar peduncle	The trial will look for hematologic and neurologic toxicity (NCI-CTCAE v 4.03).	12 weeks after virus injection
Secondary	OS12	Overall Survival at 12 months	12 months after virus injection
Secondary	Images response	Complete/partial response in MRI	12 months after virus injection
Secondary	QoL	measure quality of life baseline assessment and any changes over time	12 months after virus injection
Secondary	Samples collection	Collect tumor and blood samples for futures molecular and immune studies.	12 weeks after virus injection